Physician profile
Christopher P Gregory
NPI 1720248511
$3,498.96
in general payments reported to CMS, 2019-2025
26 companies · $782 in 2025
The $782 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $226 · 2021: $184 · 2022: $388 · 2023: $583 · 2024: $757 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872 · Travel and Lodging: $229 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.34 |
| Travel and Lodging | $229.35 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $782.56 | 2019-2025 | Rotablator Rotational Atherectomy System Console Kit, Avvigo Guidance System |
| Abbott Laboratories | $548.51 | 2024-2025 | Amplatzer Amulet, Optis |
| Novartis Pharmaceuticals Corporation | $454.16 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $338.88 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $263.97 | 2019-2024 | Xarelto |
| Heartflow, INC. | $229.35 | 2023 | Ffrct |
| Amgen INC. | $188.77 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $183.53 | 2019-2023 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $65.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.80 | 2022-2024 | |
| Irhythm Technologies, INC. | $55.43 | 2022-2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $41.60 | 2025 | |
| Philips North America LLC | $37.35 | 2024-2025 | Coronary Other, (Br3) Coronary Other |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.77 | 2024-2025 | Jardiance |
| Vital Connect, INC | $28.01 | 2024 | Vitalpatch Rtm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $25.71 | 2024 | |
| Amarin Pharma, INC. | $24.63 | 2020 | |
| Merck Sharp & Dohme LLC | $24.14 | 2022 | |
| Eisai INC. | $21.73 | 2021 | |
| Novo Nordisk INC | $16.02 | 2023 | Rybelsus, Ozempic |
| Alnylam Pharmaceuticals INC. | $14.97 | 2025 | Amvuttra |
| Seagen INC. | $13.80 | 2023 | Adcetris |
| Kowa Pharmaceuticals America, INC. | $12.90 | 2021 | |
| Medtronic, INC. | $12.88 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.08 | 2021 | |
| Angiodynamics, INC. | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.